Skip to main content

Tung T Wynn, MD

Pediatric Hematologist/Oncologist (Child Cancer Specialist)

Photo of Tung T Wynn

About me

My name is Tung Wynn, MD, and I am a board-certified pediatric hematology-oncology physician at the University of Florida. I am a clinical associate professor in the division of pediatric hematology-oncology at UF. I am also the director of the UF Pediatric Hemostasis Program and the UF Pediatric Cancer Survivorship Program. I earned my medical degree from Northeastern Ohio Medical University. After that, I completed residency, specializing in pediatrics, at the Children’s Hospital Center of Akron. Continuing to follow my passion, I completed a fellowship in hematology and oncology at Nationwide. Children’s Hospital.

My interests include hemophilia and hereditary hemorrhagic telangiectasia. I hold professional memberships with the American Society of Hematology, Florida Medical Association, Children’s Oncology Group, American Society of Clinical Oncology, American Society of Pediatric Hematology/Oncology and the American Academy of Pediatrics. As a physician, I proudly serve my community by always taking time to say hello those that I care for and by being a leader when my position calls me to be.

I chose to pursue medicine with the simple desire to help others and to be an example for them. I chose to care for pediatric hematology and oncology patients because all of my best mentors in school were all pediatric hematologists and I strived to become a physician like them. My goal as a physician is to create sustainable programs in bleeding disorders and survivorship that allows patients and their families to have a normal childhood and that prepares them for adulthood.

Outside of work, I enjoy gardening, completing small woodworking projects, learning how to can and pickle foods, perfecting southern barbeque and spending time with my wife as we watch our family grow. My favorite book genres include science fiction and mystery novels.

Accepted insurances

Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.

See all insurances

My locations

Active clinical trials

CSL222_3004

This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.

Investigator
Tung T Wynn
Status
Accepting Candidates
Ages
138 Months - 206 Months
Sexes
Male
WP45338

This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von…

Investigator
Tung T Wynn
Status
Accepting Candidates
Ages
1 Month - N/A
Sexes
All
R131L1265-HEMB-2318; BEYOND-9

Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of…

Investigator
Tung T Wynn
Status
Accepting Candidates
Ages
2 Years - N/A
Sexes
Male
View all of Dr. Wynn's active clinical trials

My research

Top areas of exploration

  • Hemophilia A , 5 publications
  • Factor VIII , 4 publications
  • Hemorrhage , 3 publications
  • Recombinant Proteins , 3 publications

Research activity

27 publications

265 citations

Why is this important?
View more of Tung Wynn's research activity

My areas of focus

Upcoming events

Stories and news

A Role Model for Hemophiliacs

Growing up the son of a football coach, Brett Sherman always had a love for sports, especially football. However, being born with hemophilia, a condition where…

View more stories related to Tung Wynn